ABG
NERV icon

Ally Bridge Group’s Minerva Neurosciences NERV Stock Holding History

Ally Bridge Group’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.97M Hold
1,655,500
– – 8.06% 2
2025
Q4 		$6.66M Buy
+1,655,500
New +$6.15M 6.93% 7

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SSC
Spruce Street Capital New York $416M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ally Bridge Group's NERV Position: Q1 2026 in Review

Ally Bridge Group held its Minerva Neurosciences (NERV) position steady in Q1 2026 at 1,655,500 shares worth $9.97M. The position accounts for 8.06% of the portfolio, ranked #2.

Ally Bridge Group first reported a position in NERV in Q4 2025 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

  • Ally Bridge Group held 1,655,500 shares of Minerva Neurosciences worth $9.97M as of Q1 2026.
  • Ally Bridge Group left its Minerva Neurosciences share count unchanged in Q1 2026.
  • Minerva Neurosciences made up 8.06% of Ally Bridge Group's portfolio in Q1 2026, its #2 holding.
  • Ally Bridge Group first reported a position in Minerva Neurosciences in Q4 2025 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.